An Intermediate Alemtuzumab Schedule Reduces the Incidence of Mixed Chimerism Following Reduced-Intensity Conditioning Hematopoietic Cell Transplantation for Hemophagocytic Lymphohistiocytosis  by Marsh, Rebecca A. et al.
Biol Blood Marrow Transplant 19 (2013) 1625e1631American Society for Blood
ASBMT
and Marrow TransplantationAn Intermediate Alemtuzumab Schedule Reduces
the Incidence of Mixed Chimerism Following
Reduced-Intensity Conditioning Hematopoietic Cell
Transplantation for Hemophagocytic Lymphohistiocytosis
Rebecca A. Marsh 1,*, Mi-Ok Kim 2, Chunyan Liu 2, Denise Bellman 1,
Laura Hart 1, Michael Grimley 1, Ashish Kumar 1, Sonata Jodele 1,
Kasiani C. Myers 1, Sharat Chandra 1, Tom Leemhuis 1, Parinda A. Mehta 1,
Jack J. Bleesing 1, Stella M. Davies 1, Michael B. Jordan 1,3,
Alexandra H. Filipovich 1
1Division of Bone Marrow Transplantation and Immune Deﬁciency, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio
2Division of Biostatistics and Epidemiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio
3Division of Immunobiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OhioArticle history:
Received 14 June 2013
Accepted 2 September 2013
Key Words:
Hemophagocytic
lymphohistiocytosis
Familial hemophagocytic
lymphohistiocytosis
Bone marrow transplantation
Hematopoietic cell
transplantation
XIAP deﬁciency
SAP deﬁciency
X-linked lymphoproliferative
disease
Reduced-intensity conditioning
AlemtuzumabFinancial disclosure: See Acknowle
* Correspondence and reprint re
of Bone Marrow Transplantation a
dren’s Hospital Medical Center, 33
E-mail address: Rebecca.Marsh
1083-8791/$ e see front matter 
http://dx.doi.org/10.1016/j.bbmt.20a b s t r a c t
Reduced-intensity conditioning (RIC) improves the outcomes of hematopoietic cell transplantation (HCT) in
patients with hemophagocytic lymphohistiocytosis (HLH). Proximal (ie, close to graft infusion) dosing of
alemtuzumab is associated with a high incidence of mixed chimerism, whereas distal (ie, distant from graft
infusion) dosing is associated with less mixed chimerism but more acute graft-versus-host disease (GVHD).
The alemtuzumab dose per kilogram of body weight also inﬂuences these outcomes. We hypothesized that an
intermediate alemtuzumab dosing schedule would reduce mixed chimerism and maintain a low incidence of
acute GVHD. In this study, 24 consecutive HCTs were performed in patients with HLH or a related disorder
using a novel intermediate alemtuzumab schedule of 1 mg/kg starting on day -14. The cumulative incidences
(CIs) of mixed chimerism, upfront acute GVHD grades II-IV, and receipt of additional hematopoietic cell
products after HCT were compared in patients treated with a distal alemtuzumab schedule (n ¼ 15) and those
treated with a proximal alemtuzumab schedule (n ¼ 33). All patients received ﬂudarabine and melphalan.
The CI of mixed chimerismwas 31% in the intermediate group, 72% in the proximal group (P < .01), and 75% in
the distal group patients who received 2 mg/kg alemtuzumab (P ¼ .03). The CI of acute GVHD grades II-IV
before the development of mixed chimerismwas 4% in the intermediate group, 0% in the proximal group, and
13% in the distal group (P ¼ .04, proximal versus distal). The 1-year CI of administration of additional
hematopoietic cell products for mixed chimerism (donor lymphocyte infusion  hematopoietic stem cell
boost  repeat HCT) was 14% in the intermediate group, 53% in the proximal group (P ¼ .01), and 38% in the
distal 2 mg/kg alemtuzumab group (P ¼ .02). Our ﬁndings indicate that intermediate RIC reduces the
incidence of mixed chimerism, is associated with a low incidence of upfront acute GVHD, and decreases the
need for additional hematopoietic cell products after HCT.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION complicated by the high incidence of mixed donor and
The use of reduced-intensity conditioning (RIC) regimens
for allogeneic hematopoietic cell transplantation (HCT) in
patients with nonmalignant disease has increased in recent
years. Speciﬁcally, RIC regimens containing alemtuzumab,
ﬂudarabine, and melphalan have shown good results and are
commonly used in the setting of primary immune deﬁciencies
[1-3]. RIC has especially been shown to improve outcomes in
patients with hemophagocytic lymphohistiocytosis (HLH),
who may suffer signiﬁcant early transplantation-related
toxicity and mortality in association with myeloablative regi-
mens. In these patients, survival after RIC is approximately
80% to 90%, compared with 45% to 70% after myeloablative
chemotherapeautic regimens [4-12].
Despite the improved survival of patients with HLH who
undergo allogeneic HCT with RIC, transplantation is oftendgments on page 1630.
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13.09.001recipient chimerism, as high as 80% [11]. This is troublesome,
because HLH disease can recur when the donor contribution
to hematopoiesis declines to less than approximately 10% to
20% [8,11]. To reduce the risk of disease recurrence or graft
loss, physicians may pursue the administration of additional
stem cell or T cell products to stabilize or increase the donor
contribution to hematopoiesis. Second transplantations are
also required in some cases. Clearly, improvements in RIC
regimens are needed to decrease the incidence of mixed
donor and recipient chimerism.
We previously reported that the timing (with relation to
graft infusion) and dose of alemtuzumab affect the devel-
opment of both mixed chimerism and acute graft-versus-
host disease (GVHD) after allogeneic HCT in patients with
HLH [11]. Patients treated with proximal alemtuzumab
schedules (close to the time of graft infusion) develop
more mixed chimerism, and less acute GVHD, compared
with patients treated with distal (more distant from the
time of graft infusion) schedules. The total dose of alem-
tuzumab per patient kilogram weight also inﬂuences these
outcomes.Transplantation.
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clonal antibody that is directed against the CD52 cell surface
glycoprotein present on lymphocytes. Because alemtuzumab
can persist at lympholytic concentrations for 1 to 2 months
after HCT [13,14], our observations may be the result of
varying degrees of in vivo lymphocyte depletion of donor
grafts, which is dependent on the presence of residual
alemtuzumab at the time of graft infusion. In fact, alemtu-
zumab dose reductions in adults have been reported to
reduce the incidence of mixed chimerism, with signiﬁcant
reductions sometimes occurring at a cost of an increase in
acute GVHD [15-17].
Based on these observations, we hypothesized that an
intermediate alemtuzumab schedule would reduce the
incidence of mixed chimerism compared with the proximal
schedule, yet maintain a low incidence of acute GVHD
compared with the increase observed in the distal schedule.
We designed a RIC regimen with an intermediate alemtu-
zumab schedule, starting on day -14 with a set dose of 1
mg/kg, with maintenance of historical ﬂudarabine and
melphalan dosing schedules. Here we compare the results of
this novel intermediate RIC protocol to the outcomes of
historical cohorts of patients with HLH and related disorders
treated with proximal and distal RIC regimens.
PATIENTS AND METHODS
Patients
Institutional Review Board permission was granted for this study.
Between 2006 and March 4, 2012, we performed 79 consecutive HCTs with
RIC regimens consisting of alemtuzumab, ﬂudarabine, and melphalan in
patients with HLH and related disorders. Seven patients were excluded from
this analysis because of changes in the alemtuzumab dosing schedule from
the protocol, owing to concomitant treatment of HLH with alemtuzumab
(n ¼ 2), temporary cessation of the preparative regimen owing to reac-
tivation of HLH (n ¼ 1) or another illness (n ¼ 2), reduction of melphalan
dose by 50% owing to concerns about toxicity in infants (n¼ 1), or receipt of
an alemtuzumab dose below that speciﬁed in the dosing protocol (n ¼ 1). In
the remaining patients, HLH and related disorders were due to defects in
XIAP/BIRC4 (n ¼ 6), SH2D1 A (n ¼ 12), PRF1 (n ¼ 7), UNC13D (n ¼ 8), STXBP2
(n ¼ 9), RAB27 A (n ¼ 1), or HLH related to an unknown genetic defect
(n ¼ 23), or the patients was found to be heterozygous for single UNC13D
mutations (n ¼ 2) or for single STXBP2 mutations (n ¼ 2), or to have single
heterozygous mutations in both UNC13D and STXBP2 (n ¼ 1) (Table 1). Of
the patients with unknown genetic defects, 1 was also diagnosed withTable 1
Patient Characteristics
Proximal RIC
(n ¼ 33)
Age at HCT, yr, median (range) 3.9 (0.25-25.5)
Underlying genetic diagnosis
PRF1 3 (9)
UNC13D 2 (6)
STXBP2 6 (18)
STX11 0
XIAP/BIRC4 4 (12)
SH2D1A 7 (21)
RAB27A 0
Unknown 9 (27)
Heterozygous for UNC13D and/or STXBP2 2 (6)
Donor match
8/8 HLA-A, -B, -C, -DR 21 (64)
1 or 2 allele mismatch 12 (36)
Donor relation
Sibling 8 (24)
Unrelated 25 (76)
Stem cell source
Bone marrow 31 (94)
Peripheral blood stem cells 2 (6)
Total nucleated cell dose,  108/kg, median (range) 7 (1.4-23.3)
CD3þ cell dose,  107/kg, median (range) 6.8 (1.8-58.8)mitochondrial disease, 2 were also diagnosed with juvenile idiopathic
arthritis, and 1 patient had been previously diagnosed with Langerhans cell
histiocytosis.
Transplantation Procedures
Twenty-four consecutive HCTswere performed in 23 patients diagnosed
with HLH or X-linked lymphoproliferative disease (XLP) using a novel
intermediate RIC protocol with an alemtuzumab dosing schedule of 1 mg/kg
divided over days -14 to -10 (Figure 1). Alemtuzumab was administered s.c.,
and the ﬁrst dose was limited to 3 mg. The cumulative incidences of mixed
chimerism and acute GVHD were compared in 2 historical cohorts of
patients with HLH and XLP treated with distal (n ¼ 15) or proximal (n ¼ 33)
RIC protocols modeled after the protocols published by Shenoy et al. [1] and
Cooper et al. [18]. The patients treated with distal RIC had a dose escalation
schedule of 3 mg/10 mg/15 mg/20 mg alemtuzumab given over days -22 to
-19. Patients weighing <10 kg received 3 mg/10 mg/10 mg/10 mg. The
patients treated with proximal RIC received either this dose escalation
schedule from day -12 to day -9 or from day -11 to day -8 (n ¼ 12) or
a cumulative 1 mg/kg dose divided over days -9 to -5 or over days -8 to -4
(n ¼ 19). Two other patients received proximal alemtuzumab dose escala-
tion schedules on alternative days, either from day -13 to day -10 or from
day -9 to day -6. All patients received ﬂudarabine 150 mg/m2 (1 mg/kg in
thoseweighing<10 kg) divided over days -8 to -4 or over days -7 to -3, along
with melphalan 140 mg/m2 (4.7 mg/kg in those weighing <10 kg) on day -3
or day -2. Graft characteristics are summarized in Table 1.
Acute GVHD prophylaxis consisted of methylprednisolone 1 to 2 mg/kg
and cyclosporine or tacrolimus (dosed to maintain a goal level of 250 to
350 ng/mL or 5 to 10 ng/mL, respectively) in all but 2 patients, who received
methylprednisolone and mycophenolate mofetil (MMF). Two patients also
received methotrexate on days þ1, þ3, and þ6. Engraftment studies were
performed using either ﬂuorescence in situ hybridization (FISH) with X and
Y chromosome probes in cases of a sex-mismatched donor or variable
number tandem repeat (VNTR) analysis in cases of a same-sex donor.
Whole-blood chimerism studies were performed at the discretion of the
primary physician and as clinically indicated, generally twice weekly,
weekly, or biweekly. All whole-blood chimerism studies were performed in
the clinical genetics laboratory at Cincinnati Children’s Hospital.
Post-Transplantation Outcomes
The time to mixed chimerism, acute GVHD, administration of donor
lymphocyte infusion (DLI), hematopoietic stem cell boost, retransplantation,
and time of death or last follow-up were obtained from laboratory and
medical records. Mixed chimerismwas deﬁned as detection of <95% donor-
derived cells in peripheral whole-blood samples onmore than 2 consecutive
occasions. Acute GVHD was graded based on standard criteria [19].
Statistical Analyses
We compared the patient characteristics listed in Table 1 among the 3
study groups using either the Kruskal-Wallis test or Fisher exact test [20,21].Intermediate RIC (n ¼ 24
HCT in 23 Patients)
Distal RIC
(n ¼ 15)
P Value
4 (0.41-24.3) 6.1 (0.43-10.8) .79
2 (9) 2 (13)
4 (17) 2 (13)
2 (9) 1 (7)
0 0
1 (4) 1 (7)
5 (22) 0
0 1 (7)
7 (30) 7 (47)
2 (9) 1 (7)
.12
21 (88) 12 (80)
3 (13) 3 (20)
1.00
6 (25) 3 (20)
18 (75) 12 (80)
.44
24 (100) 14 (93)
0 1 (7)
7.4 (2.3-15) 7 (3.2-10) .73
5.9 (2.6-16.2) 6.2 (2.1-15.7) .69
Figure 1. Schematic of alemtuzumab schedules. *Patients weighing <10 kg treated with set dosage schedules received 3 mg/10 mg/10 mg/10 mg of alemtuzumab.
#In the proximal RIC group, alemtuzumab was started on day -13 in 1 patient and on day -9 in 1 patient.
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mating cumulative incidence curves and performing comparisons using the
log-rank test [22,23]. We analyzed the time to the development of mixed
chimerism, time to the ﬁrst of any cell product intervention for mixed
chimerism (DLI and/or hematopoietic stem cell boost and/or repeat allo-
geneic HCT), and time to development of acute GVHD grade II-IV and
chronic GVHD occurring after graft infusion but before the development of
mixed chimerism (ie, upfront acute and chronic GVHD). Patients who
underwent repeat allogeneic HCT or died were not at risk for any of these
events, and repeat allogeneic HCT and death were considered competing
events. These event times are called “cause-speciﬁc” event times to distin-
guish the events of interest from the competing events. For these analyses,
patients were censored at the time of last follow-up, repeat allogeneic HCT,
or death if the events had not developed by the time of last follow-up, repeat
HCT, or death.
Overall survival was deﬁned as time to death or last follow-up if death
did not occur. We used the Kaplan-Meier estimator [24] to estimate survival
curves by groups, and used the log-rank test [22,23] to compare these
curves.
Multivariate analysis was performed with Cox proportional hazard
regression [25]. The regression modeled the hazard for overall survival
when the outcome of interest was time to death or modeled the cause-
speciﬁc hazards when the outcomes were times to cause- speciﬁc events.
We considered donor match (8/8 HLA-A, -B -C, -DRmatch versus less than 8/
8 HLA match) and total nucleated cell (TNC) dose (dichotomized around the
median cell dose of 7/kg) as covariates. For overall survival analysis, we also
considered age (dichotomized as 1 to 6 years or 7 þ years). A P value .05
was considered to indicate statistical signiﬁcance. Computations were done
using SAS (SAS Institute, Cary, NC) or XLSTAT (Addinsoft, New York, NY)
software.
RESULTS
Patients and Preliminary Analyses
In 23 patients with HLH or a related disorder, we per-
formed 24 consecutive HCTs using an intermediate RIC
regimen consisting of ﬂudarabine and melphalan coupled
with a novel intermediate alemtuzumab dosing schedule of
1 mg/kg s.c. divided over 5 days starting on day -14. We
compared outcomes in 2 retrospective cohorts of patients
with HLH and related disorders treated with distal (n ¼ 15)
or proximal (n ¼ 33) RIC regimens (Figure 1).
First, because patients treated with proximal alemtuzu-
mab received either a dose escalation schedule (n ¼ 14) or
a 1 mg/kg total dose (n ¼ 19), with timing as detailed in
Figure 1, we performed preliminary subanalyses to compare
the incidence of whole- blood mixed chimerism between
these proximal subgroups. The cumulative incidence of
mixed chimerism was 86% in the proximal group treated
with a dose escalation schedule and 61% in the proximal
group treated with 1 mg/kg alemtuzumab (P ¼ .32).
Second, we performed additional preliminary sub-
analyses to identify any signiﬁcant differences in the inci-
dence of mixed chimerism based on alemtuzumab dose per
kilogram within the proximal or distal groups. In the prox-
imal group, there was no signiﬁcant difference based onreceipt of a total alemtuzumab dose equal to or less than the
median dose of 1 mg/kg (65% versus 83%; P ¼ .77). However,
in the distal RIC group, the incidence of mixed chimerism
was signiﬁcantly lower in the 7 patients who received an
alemtuzumab dose below the median dose of 2 mg/kg
compared with the 8 patients who received 2 mg/kg (0%
versus 75%; P < .01). Given the signiﬁcant difference in the
distal group, we performed all comparisons of whole-blood
mixed chimerism among the proximal, intermediate, and
distal RIC groups both with and without subdividing the
distal RIC group.
Incidence of Whole-Blood Mixed Chimerism
We next compared the cumulative incidence of whole-
blood mixed chimerism among the intermediate, proximal,
and distal RIC schedule groups (Figure 2A). The incidence of
mixed chimerism was lower in the intermediate group
compared with the proximal group (31% versus 72%; P< .01).
This difference was also signiﬁcant with regard to each
proximal subgroup’s incidence of 61% to 86% (data not
shown; P < .01). There was a suggestion of less mixed
chimerism in the intermediate group compared with the
distal group’s cumulative incidence of 40%, but clearly less
mixed chimerism compared with the distal subgroup
patients who received 2 mg/kg alemtuzumab (31% versus
75%; P ¼ .03) (Figure 2B). No patients developed mixed
chimerism in the distal subgroup that received <2 mg/kg
alemtuzumab, compared with an incidence of 31% in the
intermediate RIC group, but the difference was not statisti-
cally signiﬁcant (P ¼ .12), perhaps because of the small
sample size. In all groups, onset of mixed chimerism gener-
ally occurred before 100 days post-HCT (Figure 2C).
We performed multivariate cause-speciﬁc hazard
modeling to control for any effect of donor match or TNC
dose. As shown in Table 2, when controlling for these effects,
mixed chimerism was signiﬁcantly increased in both the
proximal RIC group (HR, 3.11; 95% conﬁdence interval [CI],
1.30 to 7.40; P < .01) and the distal 2 mg/kg alemtuzumab
group (HR, 3.33; 95% CI, 1.10 to 10.08; P¼ .04) compared with
the intermediate group. Because no patients in the distal
subgroup who received <2 mg/kg alemtuzumab developed
mixed chimerism, we were not able to compute a HR for this
group, but this group’s lack of mixed chimerism was signif-
icant as well (P ¼ .04).
Levels of Whole-Blood Donor Chimerism
We then examined the levels of donor chimerism.Whole-
blood donor chimerism declined to <50% in 17% of the
intermediate RIC group, compared with 50% of both the
Figure 2. (A) Cumulative incidence of whole-blood mixed chimerism in the
intermediate (n ¼ 24 HCTs in 23 patients), proximal (n ¼ 33), and distal
(n ¼ 15) groups to last follow-up. (B) Cumulative incidence of whole-blood
mixed chimerism in the intermediate, proximal, and 2 distal subgroups (7
patients receiving <2 mg/kg alemtuzumab and 8 patients receiving 2 mg/kg)
to last follow-up. (C) Cumulative incidence of whole-blood mixed chimerism
in the intermediate, proximal, and distal 2 mg/kg alemtuzumab groups to
1 year.
Table 2
Multivariate Cause-speciﬁc Hazard Modeling of Whole-Blood Mixed
Chimerism
Mixed Chimerism HR (95% CI) P Value*
Intermediate RIC (n ¼ 24; HCT in 23
patients)
1.00
Proximal RIC (n ¼ 33) 3.11 (1.30-7.40) .006
Distal RIC <2 mg/kg alemtuzumab (n ¼ 7) y .0406
Distal RIC 2 mg/kg alemtuzumab (n ¼ 8) 3.33 (1.10-10.08) .0407
Donor match and total nucleated cell dose were covariates, but were not
signiﬁcant and thus are not included in the table.
* P values resulted from the likelihood ratio test. The standard test relies
on HR estimates to test for signiﬁcance. This is not applicable here because
the distal subgroup received <2 mg/kg alemtuzumab. The likelihood ratio
test is an alternative test that does not rely on the HR estimates [26].
y No patients developed mixed chimerism in the distal subgroup
receiving <2 mg/kg alemtuzumab. This suggests zero observed hazard for
the group, and so the HR estimate is not computable.
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(Figure 3). Whole-blood donor chimerism further declined to
<20% in 13% of the intermediate RIC group, compared with
25% of both the proximal and distal 2 mg/kg alemtuzumab
RIC groups (Figure 3).Cell Product Interventions for Whole-Blood Mixed
Chimerism
Patients who developed mixed donor and recipient
chimerismwere initially treated with withdrawal of immune
suppression. In addition, at the discretion of the treating
physicians, 3 patients in the intermediate RIC group (13%), 15
patients in the proximal group (45%), and 3 patients in the
distal 2 mg/kg alemtuzumab group (38%) were treated
with 1 or more DLIs and/or hematopoietic stem cell boosts
within 1 year after HCT (Table 3). The ﬁrst or sole DLI wasadministered at a median of 130 days (range, 46 to 230 days)
post-HCT in the proximal group, 62 days (range, 39 to
177 days) post-HCT in the intermediate group, and 106 days
(range, 44 to 121 days) post-HCT in the distal 2 mg/kg
group (Table 3). Many patients received additional DLIs
(Table 3), including 4% of the intermediate group, 27% of the
proximal group, and 25% of the distal 2 mg/kg dose group.
After these interventions, donor contribution to hemato-
poiesis stabilized or increased in many patients, such that
>75% of patients in each group demonstrated a >50% donor
contribution to hematopoiesis at the time of last follow-up
(Figure 3). One patient in the intermediate group and 3
patients in the proximal group required a second allogeneic
HCT. The 1-year cumulative incidence of administration of
any of these cell products for mixed chimerism
(DLI  boost  repeat HCT) was 14% in the intermediate
group, 53% in the proximal group (P ¼ .01), and 38% in the
distal 2 mg/kg dose group (P ¼ .02) (Figure 4).Upfront Acute GVHD Grades II-IV
Before the development of mixed chimerism or admin-
istration of interventions for mixed chimerism, we found
a very low incidence of acute GVHD grade II-IV in the prox-
imal and intermediate RIC groups (0% and 4%, respectively;
P ¼ .248). We observed an increased incidence of upfront
acute GVHD in the distal RIC group (13%; P ¼ .04, proximal
versus distal), with 1 patient in each distal subgroup devel-
oping upfront acute GVHD.
Unfortunately, we were not able to perform multivariate
analyses to conﬁrm these ﬁndings, owing to the very low
incidence of acute GVHD grade II-IV. However, it is notable
that all patients who developed acute GVHD before mixed
chimerism received grafts from 8/8 HLA-matched donors,
which makes a confounding effect of match unlikely.Upfront Chronic GVHD
Few patients developed upfront chronic GHVD in the
proximal RIC group (3%), intermediate RIC group (8%), and
distal RIC subgroup that received 2 mg/kg alemtuzumab
(0%). However, 2 of 7 patients in the distal RIC subgroup who
received <2 mg/kg alemtuzumab developed chronic GHVD
(29%). Both of these patients had previous grade I acute
GVHD. The cumulative incidence of chronic GVHD in the
distal <2 mg/kg RIC group was signiﬁcantly higher (33%)
compared with all of the other groups combined (6%)
(P ¼ .01).
Figure 3. Percentages of patients in each of the groups with whole-blood donor chimerism of >95%, 50-94%, 20-49%, and <20% at initial engraftment, at lowest
observation, and last follow-up. One patient in the proximal group died at day þ9 without an engraftment study and is not included.
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We next analyzed the incidences of acute GVHD grades II-
IV after interventions for mixed chimerism. The incidence of
acute GVHD grades II-IV after withdrawal of immune
suppression with or without subsequent DLI was 8% in the
intermediate group, 14% in the distal group, and 16% in the
proximal group (P ¼ .741).
Survival
Finally, we sought to determine if there was any signiﬁ-
cant effect of alemtuzumab dosing schedule on overall
survival. Kaplan-Meier analysis demonstrated similar overall
survival in all groups, ranging from 80% to 91% at 1 year
(P ¼ .49) and from 80% to 82% at last follow-up (P ¼ .56)
(Figure 5). Multivariate analysis also failed to detect any
signiﬁcant differences among the alemtuzumab schedule
groups (data not shown). Causes of death were related to
infectious complications in all groups, except for 1 patient
who died from complications of a multivisceral trans-
plantation at 2 years after HCT. Sepsis, pneumonia or pneu-
monitis with respiratory failure, acute respiratory distress
syndrome, and multiorgan failure were associated with
various organisms, including Klebsiella pneumoniae, En-
terococcus faecium, Pseudomonas aeruginosa, AcinetobacterTable 3
Additional Hematopoietic Cell Products Given after HCT
Pro
(n ¼
Patients with mixed chimerism, n (%) 23
Patients with resolution after withdrawal of immune suppression, n 2
Patients receiving ﬁrst or only DLI for mixed chimerism, n (%) 15
Day of ﬁrst DLI after HCT, median (range) 130
Whole-blood donor chimerism just before DLI, %, median (range) 41
Dose of ﬁrst or only DLI, CD3þ  106/kg, median (range) 1
Patients receiving second DLI, n (%) 9
Dose of second DLI, CD3þ  106/kg, median (range) 3
Patients receiving third DLI, n (%) 8
Dose of third DLI, CD3þ  106/kg, median (range) 10
Patients receiving fourth DLI, n (%) 8
Dose of fourth DLI, CD3þ  106/kg, median (range) 25
Patients receiving further DLI, n (%) 3
Patients developing acute GVHD grade II-IV after withdrawal of
immune suppression and/or DLI, n
5
Patients receiving CD34þ-selected boost for mixed chimerism  DLI, n 4
Patients with resolution of mixed chimerism after DLI  boost, n 6
Patients who underwent second allogeneic HCT, n 3
NA indicates not applicable.baumannii Pneumocystis jiroveci, Scedosporium apiospermum,
Paecilomyces species, Candida albicans, adenovirus, and
human metapneumovirus.
DISCUSSION
Our results demonstrate that intermediate RIC regimens
signiﬁcantly reduce the incidence of mixed chimerism after
allogeneic HCT in patients with HLH and related disorders.
Although this study is limited by our small number of
patients, both univariate and multivariate analyses support
this conclusion. This is in comparison to both proximal
alemtuzumab schedules as well the distal schedule with an
alemtuzumab dose 2 mg/kg. A distal dose of <2 mg/kg also
conveyed protection against mixed chimerism. However, we
found an increased incidence of upfront acute GVHD in the
distal RIC group and an increased incidence of chronic GVHD
in the distal subgroup with an alemtuzumab dose of <2 mg/
kg. Thus, the intermediate RIC protocol appears to better
balance the risks of mixed chimerism and upfront GVHD
compared with the other regimens.
In addition to decreasing the incidence of mixed chime-
rism, the intermediate alemtuzumab regimen appeared to
decrease the subsequent use of cell product interventions for
mixed chimerism compared with the proximal and distalximal RIC
33)
Intermediate
RIC (n ¼ 24
HCT in 23 Patients)
Distal RIC
<2 mg/kg
(n ¼ 7)
Distal RIC
2 mg/kg
(n ¼ 8)
(70) 7 (29) 0 6 (75)
2 NA 1
(45) 3 (13) NA 3 (38)
(46-230) 62 (39-177) NA 106 (44-121)
(9-71) 23 (5-25) NA 41 (29-48)
(0.02-11) 2 (1-5) NA 2 (0.4-10)
(27) 1 (4) NA 2 (25)
(0.2-12.3) 2 NA 13 (6-20)
(24) 1 (4) NA 1 (13)
(0.5-40) 4 NA 10
(24) 1 (4) NA 1 (13)
(0.5-125.6) 13.1 NA 32
(9) 1 (4) NA 1 (13)
2 NA 2
0 NA 1
1 NA 2
1 NA 0
Figure 4. One-year cumulative incidence of cell product intervention for
mixed chimerism (DLI  boost  repeat HCT).
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obvious beneﬁts to patients in terms of decreased risk of
associated morbidity and mortality and reduced psychoso-
cial and ﬁnancial burdens related to the receipt of additional
hematopoietic cell products.
Based on our results, we recommend that the 14-day
intermediate RIC regimen described herein be considered forFigure 5. Overall survival at 1 year (A) and long term (B).use in patients with HLH and related disorders. This inter-
mediate RIC regimen decreases the risk of mixed chimerism,
carries a minimal risk of upfront acute GVHD, and reduces
the need for additional hematopoietic cell products after
HCT. Future studies that prospectively correlate recipient
blood levels of alemtuzumab with the risks of mixed
chimerism and acute GVHD may promote continued
improvements to RIC HCT. Once an optimal therapeutic
range of alemtuzumab is determined, personalized dosing
protocols that target the therapeutic range can then be
developed to further optimize the outcomes of RIC HCT for
patients with HLH and related disorders.ACKNOWLEDGMENTS
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